Postoperative Reintroduction of FOLFIRI Chemotherapy Versus No Treatment
After Resection of Colorectal Liver Metastases with Response to Preoperative FOLFIRI
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-09-09
254
Participants Needed
1
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the benefit of reintroducing FOLFIRI-based chemotherapy after surgery in patients with colorectal liver metastases who responded well to preoperative FOLFIRI chemotherapy but could not receive oxaliplatin-based treatments due to contraindications. This national, multicenter, open-label phase III trial compares postoperative FOLFIRI chemotherapy to no treatment in patients who had up to 10 liver metastases removed and showed an objective response to their preoperative therapy.
Participants in the experimental group will receive postoperative FOLFIRI chemotherapy consisting of irinotecan, leucovorin, and 5-FU given biweekly for a total of 12 cycles, including the preoperative treatment cycles. The control group will not receive any postoperative treatment. The study aims to assess whether reintroducing FOLFIRI improves the rate of disease-free survival three years after surgery compared to no additional treatment.
During the trial, participants will be monitored for disease recurrence and survival outcomes over several years. Assessments include imaging to confirm no residual disease after surgery and evaluation of tumor response to prior therapy. Researchers will primarily measure the percentage of patients without disease recurrence at three years, along with overall survival and liver-specific survival rates. The study plans to enroll 254 patients and follow them for up to six years from the start of the trial.
CONDITIONS
Brief Title
Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI
Research Team
S
Stéphane BENOIST, MHD, PHD
A
Antoine BROUQUET, MHD, PHD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
No more than 10 colorectal liver metastases treated at surgery
Received 2 to 8 cycles of preoperative FOLFIRI-based chemotherapy with or without targeted therapy
Preoperative chemotherapy administered within 12 weeks before surgery
Complete or partial radiological or pathological response to preoperative therapy or stable disease
R0 or R1 resection with or without radiofrequency ablation of all liver lesions with no macroscopic residual disease
No extrahepatic or residual liver disease within 6 weeks after surgery
Tumor characterized for RAS and BRAF status
No contraindication to FOLFIRI-based chemotherapy
WHO performance status 0 or 1
Affiliated to a social security scheme
You will not qualify if you...
Palliative or R2 resection of colorectal liver metastases
Treatment of 10 or more lesions at surgery
Only radiofrequency ablation of all liver lesions without surgical resection
Presence of extrahepatic or residual metastases
No objective response to preoperative therapy
History of inflammatory bowel disease
Known UGT1A1*28 allele homozygosity
Complete absence of dihydropyrimidine dehydrogenase (DPD) activity
Contraindications to irinotecan, 5-FU, folinic acid, ondansetron, or methylprednisolone
Persistent toxicity grade 1 or higher related to preoperative FOLFIRI chemotherapy
Known pregnancy or breastfeeding women
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Approximately 6 months
Participants in the experimental group receive postoperative FOLFIRI chemotherapy biweekly for a total of 12 cycles. Participants in the control group do not receive any postoperative treatment.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of 177LuBetaBart Monoclonal Antibody for Safety and Early Effects in Adults With Advanced Solid Tumors
Evaluating 18F-T2 PETCT Imaging for Detecting Tumors with High CAIX Levels in Adults
Phase 12a Study of 64Cu-LNTH-1363S PETCT Imaging in Patients with Sarcoma or Gastrointestinal Tract Cancer
Evaluating Safety, Dosage, and Imaging Correlation with FAP Expression
Study of 18FFPyQCP PET Imaging for Fibroblast Activation Protein in Selected Cancers
Phase 2 Study of 68GaBED003 PET Imaging for Detecting Fibroblast Activation Protein in Colorectal, Gastric, Pancreatic, Breast, and Ovarian Cancers
Study Evaluating Sacituzumab Tirumotecan Alone or With Other Cancer Treatments for Advanced Gastrointestinal Cancers
Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Adults With HER2-Abnormal Locally Advanced or Metastatic Colorectal Cancer
Phase I Study of Intravenous CEA-Targeted CAR-T Therapy for Advanced CEA Positive Solid Tumors
Community Screening Study Using Polygene Methylation Testing for Colorectal Cancer in Yangzhou Residents Aged 40 to 74
Study Comparing Early and Late Onset Colorectal Cancer
Investigating Clinical, Socioeconomic, Genetic, and Molecular Factors
Assessing Cancer Recurrence and Survival Outcomes
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Postoperative chemotherapy reintroduction in good responders after colorectal liver metastases resection: A French randomized phase III trial - IRIMAD.
Camélia Labiad, Antoine Brouquet, Jean-Baptiste Bachet...